- Drug Coverage
- Hypertrophic Cardiomyopathy (HCM)
- Vaccines: 2023 Year in Review
- Eyecare
- Urothelial Carcinoma
- Women's Health
- Hemophilia
- Heart Failure
- Vaccines
- Neonatal Care
- NSCLC
- Type II Inflammation
- Substance Use Disorder
- Gene Therapy
- Lung Cancer
- Spinal Muscular Atrophy
- HIV
- Post-Acute Care
- Liver Disease
- Pulmonary Arterial Hypertension
- Safety & Recalls
- Biologics
- Asthma
- Atrial Fibrillation
- Type I Diabetes
- RSV
- COVID-19
- Cardiovascular Diseases
- Breast Cancer
- Prescription Digital Therapeutics
- Reproductive Health
- The Improving Patient Access Podcast
- Blood Cancer
- Ulcerative Colitis
- Respiratory Conditions
- Multiple Sclerosis
- Digital Health
- Population Health
- Sleep Disorders
- Biosimilars
- Plaque Psoriasis
- Leukemia and Lymphoma
- Oncology
- Pediatrics
- Urology
- Obstetrics-Gynecology & Women's Health
- Opioids
- Solid Tumors
- Autoimmune Diseases
- Dermatology
- Diabetes
- Mental Health
Walgreens, TailorMed Team Up to Deal With Prescription Abandonment: 2022 Asembia Specialty Pharmacy Summit
Many patients don’t fill their prescriptions because of the cost. TailorMed is a software platform that connects patients to possible sources of financial assistance.
Getting a prescription is one thing, filling it is another. And a large percentage — the proportion varies with the price of the medication —of patients don’t fill their prescriptions, principally because of the cost.
Sarah Freedman, a senior manager of specialty pharmacy operations, and Srulik Dvorsky, CEO of TailorMed, discussed the problem of “prescription abandonment” at a session today at the 2022 Asembia Specialty Pharmacy Summit in Las Vegas.
TailorMed is described as a financial navigation company. Founded in 2018 by Dvorsky the company’s platform uses information about the patient and their prescriptions and then links them to financial assistance programs of various kinds, such as drug coupons and government assistance programs. Dvorsky said the platform now includes about 5,000 programs that might help patients with the financial aspects of their healthcare. He said the company has attracted $35 million in investment. In November, the company acquired Vivor, another financial navigation technology company.
TailorMed signed a contract with Walgreens in June 2021. Dvorsky said the company’s software was being used in 350 of the company’s specialty pharmacies.
Freedman said that identifying financial assistance for patients is an important, but time-consuming process for pharmacists. She said TailorMed ‘s technology should help free up time for pharmacists to deal with patients.
Freedman said her background is as a retail pharmacist. “I would rather talk to them (patients) about their copay assistance and explain it than spend the time on the phone, activating cards.
One byproduct of the technology is patient empowerment, Freedman said.
“It is really important to have a patient be a managing partner in their own healthcare,” she said. “Having that autonomy, that control, means so much when you have a condition that is just taking over your life. Being able to make decisions on your own and feel educated and empowered is really important — and that is what this does.”
Cate Lockhart, executive director of the Biologics and Biosimilars Collective Intelligence Consortium, shared results yesterday of a survey that look at biosimilars on the pharmacy benefit side of coverage versus medical benefit. The survey also shared how payers and those on the pharmaceutical side are anticipating the introduction of Adalimumab (Humira®), as well as what to look for in the future of the biosimilar pipeline.
Read More
The Healthcare World According to Fein | 2023 Asembia Specialty Pharmacy Summit
May 3rd 2023Adam Fein, Ph.D., talked about some surprising trends in specialty pharmacy and healthcare at the 2023 Asembia Specialty Pharmacy Summit. The number of specialty pharmacy locations may be peaking. And that "gross-to-net bubble" in drug prices that Fein has written about so much — well, it may be shrinking.
Read More
